BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16387135)

  • 1. Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years.
    Sanchez EQ; Martin AP; Ikegami T; Uemura T; Narasimhan G; Goldstein RM; Levy MF; Chinnakotla S; Dawson S; Randall HB; Saracino G; Klintmalm GB
    Transplant Proc; 2005 Dec; 37(10):4416-23. PubMed ID: 16387135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
    Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
    Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
    Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus experience in heart transplantation.
    Aranda-Dios A; Lage E; Sobrino JM; Mogollón MV; Guisado A; Cabezón S; Hinojosa R; Hernández A; Ordóñez A
    Transplant Proc; 2006 Oct; 38(8):2547-9. PubMed ID: 17097997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
    Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reviewing the evidence for de novo immunosuppression with sirolimus.
    Flechner SM
    Transplant Proc; 2008 Dec; 40(10 Suppl):S25-8. PubMed ID: 19100902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients.
    Morard I; Dumortier J; Spahr L; Hadengue A; Majno P; Morel P; Mentha G; Giostra E
    Liver Transpl; 2007 May; 13(5):658-64. PubMed ID: 17457887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion from calcineurin inhibitors to sirolimus in kidney transplant recipients: a retrospective cohort study.
    Cardinal H; Froidure A; Dandavino R; Daloze P; Hébert MJ; Colette S; Boucher A
    Transplant Proc; 2009 Oct; 41(8):3308-10. PubMed ID: 19857737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome.
    Perrakis A; Schwarz K; Yedibela S; Croner RS; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3702-7. PubMed ID: 22172830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients.
    Rogers CC; Johnson SR; Mandelbrot DA; Pavlakis M; Horwedel T; Karp SJ; Egbuna O; Rodrigue JR; Chudzinski RE; Goldfarb-Rumyantzev AS; Hanto DW; Curry MP
    Clin Transplant; 2009; 23(6):887-96. PubMed ID: 19681971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation.
    Zaghla H; Selby RR; Chan LS; Kahn JA; Donovan JA; Jabbour N; Genyk Y; Mateo R; Gagandeep S; Sher LS; Ramicone E; Fong TL
    Aliment Pharmacol Ther; 2006 Feb; 23(4):513-20. PubMed ID: 16441472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
    Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
    Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the efficacy and safety of a slow conversion from calcineurin inhibitor- to sirolimus-based therapies in maintenance renal-transplant patients presenting with moderate renal insufficiency.
    Kamar N; Frimat L; Blancho G; Wolff P; Delahousse M; Rostaing L
    Transpl Int; 2007 Feb; 20(2):128-34. PubMed ID: 17239020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.